Satoshi Gando Selected Research

Leukocyte Elastase (Neutrophil Elastase)

7/2013	Coagulofibrinolytic changes in patients with disseminated intravascular coagulation associated with post-cardiac arrest syndrome--fibrinolytic shutdown and insufficient activation of fibrinolysis lead to organ dysfunction.
12/2012	A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis.
2/2011	Disseminated intravascular coagulation at an early phase of trauma is associated with consumption coagulopathy and excessive fibrinolysis both by plasmin and neutrophil elastase.
1/2010	Sivelestat (selective neutrophil elastase inhibitor) improves the mortality rate of sepsis associated with both acute respiratory distress syndrome and disseminated intravascular coagulation patients.
12/2008	The response of antithrombin III activity after supplementation decreases in proportion to the severity of sepsis and liver dysfunction.
5/2008	Insufficient production of urinary trypsin inhibitor for neutrophil elastase release after cardiac arrest.
1/2007	The activation of neutrophil elastase-mediated fibrinolysis is not sufficient to overcome the fibrinolytic shutdown of disseminated intravascular coagulation associated with systemic inflammation.
1/2005	Serial changes in neutrophil-endothelial activation markers during the course of sepsis associated with disseminated intravascular coagulation.
1/2003	Imbalances between the levels of tissue factor and tissue factor pathway inhibitor in ARDS patients.
12/2002	Combined activation of coagulation and inflammation has an important role in multiple organ dysfunction and poor outcome after severe trauma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Satoshi Gando Research Topics

Disease

71	Disseminated Intravascular Coagulation 01/2022 - 01/2003
57	Sepsis (Septicemia) 01/2022 - 08/2002
31	Thrombosis (Thrombus) 01/2022 - 12/2002
30	Wounds and Injuries (Trauma) 01/2022 - 12/2002
22	Multiple Organ Failure (MODS) 01/2022 - 08/2002
21	Inflammation (Inflammations) 01/2022 - 12/2002
18	Hemorrhage 01/2022 - 04/2005
16	Systemic Inflammatory Response Syndrome (Sepsis Syndrome) 08/2017 - 08/2002
14	Critical Illness (Critically Ill) 02/2016 - 10/2003
11	Shock 01/2018 - 10/2003
10	Septic Shock (Toxic Shock Syndrome) 11/2020 - 08/2002
9	Heart Arrest (Cardiac Arrest) 01/2022 - 05/2008
9	Infections 02/2021 - 01/2005
7	Out-of-Hospital Cardiac Arrest 01/2021 - 05/2008
7	Acute Lung Injury 01/2020 - 11/2004
6	Endotoxemia 09/2006 - 12/2002
5	Hypoxia (Hypoxemia) 01/2022 - 07/2011
5	Hypothermia 05/2020 - 11/2013
5	Hypotension (Low Blood Pressure) 10/2017 - 12/2002
4	COVID-19 01/2022 - 01/2020
4	Post-Cardiac Arrest Syndrome 01/2022 - 07/2013
3	Body Weight (Weight, Body) 05/2015 - 12/2008
3	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 02/2013 - 01/2003
2	Thromboinflammation 01/2022 - 01/2021
2	Lung Injury 01/2022 - 01/2010
2	Frailty 08/2021 - 01/2021
2	Neoplasms (Cancer) 01/2020 - 06/2011
2	Heart Failure 01/2020 - 02/2016
2	Acidosis 03/2016 - 02/2015
1	Pneumonia (Pneumonitis) 01/2022

Drug/Important Bio-Agent (IBA)

71	Dacarbazine (DIC)FDA LinkGeneric 01/2022 - 08/2002
17	FibrinIBA 01/2022 - 01/2007
15	AntithrombinsIBA 01/2022 - 12/2006
11	ThrombomodulinIBA 01/2022 - 12/2002
11	Leukocyte Elastase (Neutrophil Elastase)IBA 07/2013 - 08/2002
10	Thrombin FDA Link 01/2022 - 07/2011
9	AnticoagulantsIBA 01/2022 - 02/2006
8	Plasminogen Activators (Plasminogen Activator)IBA 01/2021 - 01/2007
8	Fibrinogen (Factor I)FDA Link 09/2019 - 12/2006
8	Hemostatics (Antihemorrhagics)IBA 03/2016 - 12/2003
7	Protein CIBA 12/2018 - 12/2003
6	fibrin fragment D (D-dimer)IBA 01/2022 - 01/2007
6	Fibrin Fibrinogen Degradation ProductsIBA 08/2017 - 01/2007
6	Proteinase-Activated ReceptorsIBA 05/2014 - 11/2004
6	Thromboplastin (Tissue Factor)IBA 07/2013 - 08/2002
5	Fibrinolysin FDA Link 01/2022 - 01/2007
5	estropipate (Ogen)FDA LinkGeneric 01/2022 - 07/2011
5	Lactic Acid (Lactate)FDA LinkGeneric 01/2021 - 02/2011
5	EndotoxinsIBA 11/2020 - 10/2003
5	Anti-Bacterial Agents (Antibiotics)IBA 03/2020 - 06/2010
5	formycin diphosphate (FDP)IBA 08/2017 - 01/2007
5	Vasoconstrictor AgentsIBA 05/2014 - 10/2003
4	CytokinesIBA 01/2021 - 02/2010
4	Peptides (Polypeptides)IBA 05/2014 - 12/2006
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2013 - 06/2006
4	LipopolysaccharidesIBA 04/2007 - 12/2002
3	Angiotensin IIIBA 01/2022 - 09/2006
3	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2015
3	Complement System Proteins (Complement)IBA 01/2021 - 11/2017
3	Heparin (Liquaemin)FDA LinkGeneric 01/2020 - 01/2014
3	Biomarkers (Surrogate Marker)IBA 09/2019 - 11/2007
3	Epinephrine (Adrenaline)FDA LinkGeneric 01/2019 - 01/2013
3	Endothelins (Endothelin)IBA 05/2014 - 09/2006
3	Antifibrinolytic Agents (Antifibrinolytics)IBA 07/2011 - 11/2009
3	Antithrombin IIIIBA 10/2009 - 12/2006
3	Protein Isoforms (Isoforms)IBA 04/2007 - 10/2003
3	Histamine (Histamine Dihydrochloride)FDA Link 04/2005 - 12/2002
2	Histones (Histone)IBA 01/2022 - 01/2021
2	Blood Glucose (Blood Sugar)IBA 01/2020 - 01/2015
2	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2019 - 02/2011
2	Proteins (Proteins, Gene)FDA Link 02/2013 - 04/2007
2	Carboxypeptidase B2 (Thrombin Activatable Fibrinolysis Inhibitor)IBA 12/2012 - 02/2011
2	Tranexamic Acid (AMCA)FDA Link 07/2011 - 03/2011
2	Macrophage Migration-Inhibitory FactorsIBA 06/2011 - 08/2007
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2008 - 08/2007
2	urinastatin (MR 20)IBA 05/2008 - 01/2007
2	Plasminogen Activator Inhibitor 1IBA 01/2007 - 11/2004
2	Nitric Oxide Synthase (NO Synthase)IBA 06/2006 - 10/2003
2	NF-kappaB decoyIBA 04/2005 - 12/2004
2	NF-kappa B (NF-kB)IBA 04/2005 - 12/2004
2	OligodeoxyribonucleotidesIBA 04/2005 - 12/2004
2	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 01/2005 - 12/2002
2	SelectinsIBA 01/2005 - 12/2002
2	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 01/2005 - 12/2002
2	lipoprotein-associated coagulation inhibitor (TFPI)IBA 01/2003 - 08/2002
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2022
1	antiglomerular basement membrane antibodyIBA 01/2022

Therapy/Procedure

12	Therapeutics 01/2022 - 01/2010
9	Resuscitation 01/2022 - 09/2012
8	Critical Care (Surgical Intensive Care) 01/2020 - 01/2008
4	Cardiopulmonary Resuscitation (CPR) 01/2016 - 05/2009
3	Extracorporeal Membrane Oxygenation 01/2022 - 02/2016
3	Patient Care Bundles 01/2022 - 11/2019
3	Artificial Respiration (Mechanical Ventilation) 01/2022 - 08/2013
3	Hemodiafiltration 01/2015 - 10/2003
2	Glycemic Control 10/2021 - 02/2014
2	Length of Stay 08/2021 - 01/2021
2	Catheters 01/2016 - 10/2005
2	Blood Transfusion (Blood Transfusions) 03/2011 - 01/2010
2	Continuous Renal Replacement Therapy 05/2009 - 07/2006